ClinicalTrials.gg
RecruitingNCT07934953Updated Nov 13, 2026

Effect of Oral Diamine Oxidase on Symptoms Induced by Histamine Oral Challenge

An interventional study of Diamine Oxidase (DAO) and Placebo in Histamine Intolerance, Food Hypersensitivity and Histamine Sensitivity, sponsored by DR Healthcare - biotexia. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by DR Healthcare - biotexia · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Food Hypersensitivity with a site in Spain — 8 open to participants now, 10 under way, 3 of them phase 3. Food Hypersensitivity · Spain.

Planned enrollment
13th of 19
60 · median 68
Started
2026
with 1 other
No phase
11 of 23
3 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
DR Healthcare - biotexia

Among the 23 studies in Food Hypersensitivity with a site in Spain, this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 23rd registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 92 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

8 of the 23 studies in Food Hypersensitivity with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 54 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 42 (78%) stop at 75 or younger; 46 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Food Hypersensitivity with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether oral diamine oxidase (DAO) can lower symptoms caused by an oral histamine challenge in adults with self-reported food-related histamine symptoms who demonstrate responsiveness to histamine challenge during screening.

Read the detailed description

Histamine intolerance is characterized by the occurrence of symptoms after ingestion of histamine-containing foods and may be associated with reduced degradation of dietary histamine by the enzyme diamine oxidase (DAO). Previous studies have suggested potential benefits of oral DAO supplementation; however, additional controlled clinical studies are needed using standardized histamine challenge procedures and predefined symptom assessments.

This study is a randomized, double-blind, placebo-controlled, crossover trial conducted in healthy adult volunteers who demonstrate a predefined response to histamine provocation are randomized into the treatment phase.

03

Conditions studied

  • Histamine Intolerance
  • Food Hypersensitivity
  • Histamine Sensitivity
  • DAO Deficiency

Browse trials for

Keywords

  • Diamine Oxidase
  • DAO
  • Histamine Challenge
  • Histamine Provocation
  • Histamine Sensitivity
  • Histamine Intolerance
  • Dietary Histamine
  • Food-Related Symptoms
  • Oral Challenge Test
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years.
  • History of symptoms after consumption of foods potentially rich in histamine.
  • Clinically stable and suitable for oral histamine challenge testing.
  • Ability and willingness to provide .
  • Willingness to comply with study procedures and restrictions.
  • No medical history.
  • No clinically significant findings during screening assessments.
  • Positive response to histamine challenge during screening, according to predefined protocol criteria.

Exclusion criteria

Exclusion Criteria:

  • Food allergy, celiac disease, peptic ulcer disease, or esophagitis.
  • Acute infection.
  • Pregnancy or breastfeeding.
  • History of anaphylaxis or severe reactions to histamine.
  • Known intolerance to diamine oxidase.
  • Severe chronic diseases or medical conditions that may increase risk.
  • Excessive alcohol consumption.
  • Positive drug or alcohol screening.
  • Use of medications that may interfere with histamine or DAO activity.
  • Severe reaction during screening histamine challenge.
  • Any condition that, in the investigator's opinion, may compromise participant safety or study conduct.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    DAO

    Dietary Supplement: Diamine Oxidase (DAO)

  • Placebo comparator
    Placebo

    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementDiamine Oxidase (DAO)

    Oral diamine oxidase (DAO) dietary supplement administered before a standardized oral histamine challenge in a randomized, double-blind, crossover study.

  • Dietary supplementPlacebo

    Matching placebo capsule administered before a standardized oral histamine challenge in a randomized, double-blind, crossover study.

06

What researchers measure

Primary outcomes

  1. Overall symptom burden following oral histamine challenge

    Overall symptom burden is assessed using a study-specific symptom rating scale covering three domains: gastrointestinal, cutaneous/mucosal, and headache/neurovegetative symptoms. Each domain is rated from 0 (no symptoms) to 10 (maximum imaginable symptom intensity), resulting in a total score ranging from 0 to 30, with higher scores indicating greater symptom burden. The primary outcome is the area under the curve (AUC) of the total symptom score over the first 4 hours following the histamine challenge.

    Time frame: 0 to 4 hours after histamine challenge

07

Study locations

2 of 2 sites recruiting
  • Centre d'Investigació del Medicament (CIM-IR Sant Pau)
    Barcelona, Barcelona 08041, Spain
    Recruiting
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain 08041, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2027, 5 months after the start.

Of 85 interventional studies with no phase under Food Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Nov 13, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934953
Lead sponsor
DR Healthcare - biotexia
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Sep 1, 2026
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Carlos de Lecea, MD
Contact
cdelecea@biotexia.com
+34 609 02 53 61
Alejandra Gadea, PhD
Contact
agadea@biotexia.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion